Entrada Therapeutics, Inc. (TRDA)
After hours:
| Previous close | 15.74 |
| Open | 15.40 |
| Bid | 11.24 x 200 |
| Ask | 19.77 x 200 |
| Day's range | 15.33 - 15.68 |
| 52-week range | 10.75 - 18.44 |
| Volume | |
| Avg. volume | 73,960 |
| Market cap | 526.303M |
| Beta (5Y monthly) | -0.23 |
| PE ratio (TTM) | 22.59 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday
- GlobeNewswire
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York, NY. The fireside chat will be
- GlobeNewswire
Entrada Therapeutics Reports First Quarter 2024 Financial Results
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement of its Phase 1/2 clinical trial of VX-670 for DM1 – – Cash runway expected through the second quarter of 2026 with $327 million in cash, cash equivalents and marketable securities as of March 31, 2024 – BOSTON, May 07, 2024 (GLOBE NEWSWIRE) --
